--- name: kidney-international description: Use when targeting Kidney International or deciding whether a nephrology or hypertension clinical/translational study fits this venue. Encodes the journal's fit with a global ISN perspective, the evidence and mechanistic bar, reporting-guideline and registration requirements, ISN house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice. --- # Kidney International (kidney-international) ## Journal positioning Kidney International is the flagship journal of the International Society of Nephrology (ISN), publishing high-impact nephrology and hypertension research with an explicitly **global, international perspective** across clinical and translational science: kidney disease epidemiology and trials, dialysis and transplantation, and mechanistic kidney biology with clear human relevance. Its defining expectation is a **clinically or translationally important advance in kidney health that matters across diverse health systems and populations**, with strong representation of global-health, epidemiologic, and outcomes nephrology alongside disease mechanism — not a narrow single-center series or a basic experiment with no human anchor. Compared with the U.S.-society sibling, KI leans toward international clinical breadth and translational relevance. This skill is a **fit / venue-selection / re-framing** aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live Kidney International author instructions. ## When to trigger - The author names Kidney International for a nephrology, hypertension, or kidney translational study and wants a fit/framing check. - A kidney study must be re-framed around international clinical relevance, outcomes, or disease mechanism with human anchoring. - The author is choosing between Kidney International and the Journal of the American Society of Nephrology (ASN flagship), or general medicine. - The author needs the journal's reporting-guideline, registration, and global-health/ epidemiology expectations. ## Scope & topic fit - Clinical nephrology and hypertension: CKD, AKI, glomerular disease, and blood-pressure/ kidney interactions across diverse populations. - Kidney-disease epidemiology and global-health nephrology: burden, access, and outcomes across health systems and resource settings. - Dialysis and transplantation: outcomes, modality, access, and organ-preservation research with international relevance. - Translational kidney science: biomarkers, genetics/genomics, and mechanism studies with validated human relevance. - Clinical trials and large multinational cohorts with kidney endpoints. - Hypertension and cardio-renal research connecting kidney function to systemic outcomes. ## Method & evidence bar - Clinical studies must be adequately powered with prespecified, patient-centered kidney endpoints; trials require prospective registration and the registration number. - The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE for observational/epidemiologic work, PRISMA for systematic reviews, ARRIVE for animal studies. - Epidemiologic and global-health studies must address representativeness, confounding, bias, and generalizability across settings explicitly. - Translational claims need validated human relevance (tissue, biofluids, or cohorts); basic experiments need controls and biological replication. - Effect estimates need confidence intervals and absolute as well as relative measures; causal language must match the design. - eGFR/biomarker methods, kidney-outcome definitions, and statistical-analysis plans must be explicit. ## Structure & house style - ISN format with a structured abstract and a translational/lay-significance statement; re-check current article types (Clinical Investigation, Basic Research, etc.) and limits on the live guide. - The introduction frames the global clinical or biological gap; the discussion states the practice implication and bounds generalizability. - A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design; animal work reports ARRIVE-aligned detail. - Figures show representative data with statistics and N; a supplement carries full methods, the protocol/SAP, and additional analyses. ## Official-submission checklist - Before giving submission-ready advice, read `../../resources/source-basis.md` and `../../resources/official-source-map.md`; start from the ICMJE/EQUATOR and ISN anchors, then cite the current Kidney International page you checked. - Search the live site for "Kidney International ISN instructions for authors" and follow the current version. - Re-check article types, abstract and significance-statement format, and word/figure/reference limits. - Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE), data/code-availability, and protocol/SAP submission. - Re-check IRB/ethics and consent, transplant-donor consent where relevant, animal-care/IACUC approval, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure. - If the live official instructions conflict with this skill, the official instructions win. ## Pre-submission self-check - [ ] The study delivers a clinically/translationally important kidney finding with relevance across settings. - [ ] Clinical kidney endpoints are prespecified and powered; trials are registered with the number in the manuscript. - [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached. - [ ] Epidemiologic work addresses representativeness, confounding, and generalizability. - [ ] Translational claims are anchored to validated human relevance; basic work shows controls and replication. - [ ] IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared. ## Common desk-reject triggers - Single-center descriptive series with limited generalizability and no broader relevance. - Epidemiologic analyses with inadequate confounding control or overstated causal claims. - Basic experiments with no human anchor, replication, or ARRIVE-aligned rigor. - Missing trial registration, protocol, or the required reporting checklist. - Incremental dialysis/transplant or hypertension outcome reports with limited novelty or scope. ## Re-routing decision - U.S.-society, mechanism-forward nephrology with deep basic science → `journal-of-the-american-society-of-nephrology`. - Diabetic kidney disease centered on endocrine/metabolic mechanism → `diabetologia` / `journal-of-clinical-endocrinology-and-metabolism`. - Critical-care AKI dominated by ICU organ-support → `critical-care-medicine` / `american-journal-of-respiratory-and-critical-care-medicine`. - Broad practice-changing nephrology trial → general medicine (`jama` / NEJM / The Lancet in the natural-science bundle). - Pure renal cell biology with no disease/population anchor → a basic-science venue in the natural-science bundle. ## Output format ```text [Fit] High / Medium / Low (one-line reason) [Target] Kidney International (ISN) [Specialty tags] [Study design / reporting guideline] [Method/evidence] [Top risk] [Official items to re-check]
[Re-route suggestion] ```